Investment Thesis
Azitra is a pre-revenue pharmaceutical company with zero sales and mounting operating losses (-$3.9M), indicating an unproven business model with high execution risk. While the balance sheet is strong with $10.1M cash and minimal debt providing approximately 4 years of runway at current burn rates, the company remains entirely dependent on R&D success with no commercial products generating revenue.
Strengths
- Strong cash position ($10.1M) representing 83% of total assets with zero debt
- Excellent liquidity ratios (6.94x current and quick ratio) providing financial flexibility
- Manageable cash burn rate (~$2.5M annually) relative to cash reserves with improving EPS trend
Risks
- Zero revenue with no commercial products - completely unproven business model and market viability
- Negative operating cash flow and persistent operating losses worsening year-over-year in absolute terms
- Typical biotech execution risk including dependence on successful clinical trials, regulatory approvals, and market adoption
- Limited financial runway despite cash position - company must achieve commercial success or face depletion
Key Metrics to Watch
- Revenue generation timeline and first commercial product launch date
- Quarterly cash burn rate trend and operating cash flow trajectory
- Clinical trial progress and regulatory milestone announcements
- Cash runway extension through capital raises or partnership announcements
Financial Metrics
Revenue
0.0
Net Income
-3.9M
EPS (Diluted)
$-0.25
Free Cash Flow
-2.5M
Total Assets
12.1M
Cash
10.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-37.5%
ROA
-32.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
6.94x
Quick Ratio
6.94x
Debt/Equity
0.00x
Debt/Assets
13.6%
Interest Coverage
-4,299.37x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T07:58:07.822353 |
Data as of: 2026-03-31 |
Powered by Claude AI